Artisan Partners Limited Partnership Has $184.93 Million Stake in Twist Bioscience Corporation $TWST

Artisan Partners Limited Partnership trimmed its position in shares of Twist Bioscience Corporation (NASDAQ:TWST) by 9.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 5,830,205 shares of the company’s stock after selling 580,695 shares during the quarter. Artisan Partners Limited Partnership owned approximately 0.10% of Twist Bioscience worth $184,934,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also made changes to their positions in TWST. Royal Bank of Canada lifted its holdings in shares of Twist Bioscience by 11.8% during the 1st quarter. Royal Bank of Canada now owns 40,373 shares of the company’s stock valued at $1,585,000 after buying an additional 4,254 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Twist Bioscience by 4.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 70,310 shares of the company’s stock valued at $2,765,000 after buying an additional 3,181 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in shares of Twist Bioscience by 4.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 932,978 shares of the company’s stock valued at $36,629,000 after buying an additional 37,577 shares during the last quarter. Intech Investment Management LLC lifted its holdings in shares of Twist Bioscience by 18.9% during the 1st quarter. Intech Investment Management LLC now owns 28,917 shares of the company’s stock valued at $1,135,000 after buying an additional 4,591 shares during the last quarter. Finally, Norges Bank bought a new position in shares of Twist Bioscience in the 2nd quarter valued at approximately $737,000.

Insider Buying and Selling

In other Twist Bioscience news, CEO Emily M. Leproust sold 8,061 shares of Twist Bioscience stock in a transaction that occurred on Wednesday, April 22nd. The stock was sold at an average price of $65.29, for a total value of $526,302.69. Following the transaction, the chief executive officer directly owned 858,887 shares of the company’s stock, valued at $56,076,732.23. The trade was a 0.93% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Dennis Cho sold 402 shares of Twist Bioscience stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $69.84, for a total value of $28,075.68. Following the completion of the transaction, the insider directly owned 119,692 shares in the company, valued at approximately $8,359,289.28. This represents a 0.33% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 33,170 shares of company stock worth $1,948,964. 3.08% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on TWST shares. Robert W. Baird raised their price objective on Twist Bioscience from $50.00 to $65.00 and gave the company an “outperform” rating in a research note on Tuesday, May 5th. Barclays raised their price objective on Twist Bioscience from $55.00 to $65.00 and gave the company an “overweight” rating in a research note on Monday, May 4th. Leerink Partners set a $80.00 price objective on Twist Bioscience in a research note on Friday, May 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Twist Bioscience in a research note on Friday, March 27th. Finally, Guggenheim raised their price objective on Twist Bioscience from $55.00 to $60.00 and gave the company a “buy” rating in a research note on Tuesday, May 5th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $71.60.

Twist Bioscience Stock Performance

Shares of NASDAQ TWST opened at $84.95 on Wednesday. The company has a quick ratio of 2.42, a current ratio of 2.70 and a debt-to-equity ratio of 0.03. The business’s 50 day moving average is $60.98 and its two-hundred day moving average is $48.30. The company has a market cap of $5.29 billion, a P/E ratio of -63.87 and a beta of 2.23. Twist Bioscience Corporation has a 12 month low of $23.30 and a 12 month high of $86.94.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings results on Monday, May 4th. The company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.22). The business had revenue of $110.72 million during the quarter, compared to the consensus estimate of $107.64 million. Twist Bioscience had a negative return on equity of 26.73% and a negative net margin of 19.85%.The business’s quarterly revenue was up 19.3% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.66) earnings per share. On average, equities analysts expect that Twist Bioscience Corporation will post -2.02 EPS for the current year.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.